Compare Becton Dickinson and Co (BDX) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Nutanix Inc — how do they compare? Becton Dickinson and Co trades at $180.01 (market cap $49.41B), while Nutanix Inc trades at $63.79 (market cap $17.39B). The key difference: Becton Dickinson and Co is far larger — about 2.8× Nutanix Inc's market cap, and Becton Dickinson and Co pays a 2.32% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals.
| BDX | NTNX | |
|---|---|---|
Market Cap | $49.41B | $17.39B |
Sector | Health | Technology |
52-Week High | $185.39 | $81.12 |
52-Week Low | $138.62 | $34.41 |
Enterprise Value | $65.51B | $16.90B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
Nutanix (NTNX) trades at $63.74, down 1.12% today, showing strong fundamental momentum with consistent earnings beats and robust revenue growth. The stock maintains a bullish technical outlook with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. Recent institutional buying activity and positive analyst sentiment (62.5% buy ratings) reflect confidence in the hybrid multicloud platform's growth trajectory.
Outlook remains positive with Q4 earnings expected to beat consensus, though supply chain constraints pose near-term risks. The company's expanding profit margins and VMware migration opportunities provide upside potential, but elevated valuation metrics (P/E 67.71) require continued execution. Investors should monitor Q2 2026 earnings results due August 26th for confirmation of growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
